Arch Biopartners Inc.: federal grants and contributions: 5 agreements; $9.8M value; 2 departments; 2 programs.
Assay record ASY-CA-0FQBUY417Z · Cite as: Assay Systems, “Arch Biopartners Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/arch-biopartners-inc/
This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe cases of COVID-19, specifically in the lungs, kidney and liver.
The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candidate and selective dipeptidase-1 inhibitor which blocks injury in the lungs and kidneys by reducing leukocyte recruitment and inflammation in these organs. This project focuses on completing the clinical and commercial drug development tasks needed to obtain regulatory approval for LSALT peptide. A successful project will advance the LSALT peptide as a new therapeutic that will reduce organ infla
LSALT is a peptide drug and a selective non-enzymatic dipeptidase-1 antagonist and prevents leukocyte adhesion to endothelial cells creating numerous indications for targeting inflammation in the context of microbial and non-microbial (sterile) tissue injury. In pre-clinical mouse models, LSALT has proven efficacious in preventing acute kidney injury induced by ischemia-reperfusion, toxins and sepsis. LSALT patents have been assigned to Arch Biopartners Inc. who will manage drug development and human clinical trials for acute kidney injury as the first indication. Identification of new and mor
All grants from Innovation, Science and Economic Development Canada
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.